Pharma News – Oct. 16, 2019

Your regular dose of interesting tidbits from around the pharma web…

 

California Governor Gavin Newsome recently signed a bill, Assembly Bill 824, to outlaw the practice of pharma companies settling patent infringement lawsuits brought by generic manufacturers to delay their research or release of generic versions of drugs. The bill would treat this as anti-competitive and would open the possibility of a civil lawsuit. (Policymed.com)

 

Hospitals and other players may soon be able to donate certain cybersecurity software to physicians without fear of violating the Stark Law or the Anti-Kickback Statue to help combat the rash of hospital and other institutions being held hostage by cyber criminals. (medtechdive.com)

 

Bayer recently announced signing agreements with 11 digital health startups. As part of the program, Bayer will support these startups with the aim of developing long-term agreements to help drive forward research in a variety of areas. (worldpharmanews.com)

 

Devoted Health has entered into an agreement with Apple to defray the cost of an Apple watch by $150 for it members. Apple has been in discussion with other healthcare groups but its partnership with Devoted Health is the first foray into the senior healthcare field. (cnbc.com)

 

Canada’s department of health has increased transparency to the public in how it handles the significant amount of data that comes from companies when they apply for a new drug, medical device, etc. Transparency advocates also say that this will help medical societies determine the best way to setup guidelines for the treatment’s use and whether articles submitted to journals are accurate. (npr.org)

 

What does your Medcomm agency need to do to go from managing 200 events to 20,000 events? How do you go beyond mere execution to proactively measure ROI, ensure compliance, and provide a new value to pharma clients?

Read our latest blog for the top “5 Things Medcomms Need to Do for Better Speaker Program Management.”

 

–  To find out more about Pharmagin, Contact Us  –

en_USEnglish
en_USEnglish